William Blair & Company
ITCI

William Blair & Company’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

William Blair & Company’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,820
Closed -$791K – 1777
2020
Q2 		$791K Buy
+30,820
New +$624K ﹤0.01% 792

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair & Company's ITCI Position: Q3 2020 in Review

William Blair & Company sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2020, closing a stake of 30,820 shares — an estimated $791K sold.

William Blair & Company first reported a position in ITCI in Q2 2020 and held it in 1 quarter. The position peaked at $791K in Q2 2020. 176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • William Blair & Company reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2020 after selling out during the quarter.
  • William Blair & Company sold 30,820 Intra-Cellular Therapies Inc. shares in Q3 2020, an estimated $791K.
  • William Blair & Company first reported a position in Intra-Cellular Therapies Inc. in Q2 2020 and held it in 1 quarter.
  • William Blair & Company's Intra-Cellular Therapies Inc. position peaked at $791K in Q2 2020.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on William Blair & Company's 13F filing for Q3 2020, filed 6 Nov 2020.